Working with the leading research institutions, Uniseed and the Medical Research Commercialisation Fund (MRCF) fill a unique niche in the Australian investment landscape by investing in early stage break-through ideas. By bridging the infamous “valley of death” they take bright innovations from the bench through proof-of-concept to successful ready-for-exit start-ups.

We are fortunate to be joined by two investment managers Dr Anthony Musumeci (Uniseed) and Dr Mike Molinari (MRCF) for this interactive presentation where they will talk about their respective funds. We will hear some of the news-making start-up success stories as well as firsthand advice on what they look for in potential investments.

About Uniseed and MRCF:
Uniseed’s mandate is to facilitate the commercialisation of intellectual property by targeted investment in highly promising opportunities across a wide range of technology sectors (including healthcare and advanced materials). Uniseed started its third and largest fund in November 2015 with $50M of capital committed and is on an active look out for investment opportunities.

MRCF focuses on medical technologies and brings together more than 50 of Australia’s leading medical research institutes (including the AIBN) and research hospitals, the Australian Government, New Zealand Government and the state governments of Victoria, New South Wales, Western Australia, Queensland and South Australia. The team is currently investing from the $200M MRCF3 fund, raised in 2015.

About AIBN Seminar Series

The AIBN Seminar series showcases a range of seminars across different topics and disciplines